Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCME: Lisdexamfetamine and Contingency Management for Methamphetamine Use Disorder
NCT05854667Phase 2Recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lisdexamfetamine in methamphetamine use disorder (MUD) (4 arms), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Total number of days of methamphetamine use during maintenance phase at 12 weeks. Started Dec 2023; status: recruiting.
02
Drugs
lisdexamfetamine
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT05854667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05854667.